{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-142232","form_type":"8-K","ticker":"DYN","cik":"0001818794","company_name":"Dyne Therapeutics, Inc.","filed_at":"2024-05-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:20.337540+00:00","generated_at":"2026-06-01T13:11:06.587185+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Dyne: DYNE-101 achieves 27% splicing correction at 3 months; DYNE-251 shows 3.22% dystrophin expression in DMD","bullets":["DYNE-101 5.4 mg/kg Q8W showed 27% mean splicing correction across 22-gene panel at 3 months, all participants responded.","DYNE-101 improved myotonia (vHOT) by 4.5 sec at 3 months (5.4 mg/kg) and 4.4 sec at 12 months (1.8 mg/kg Q4W).","DYNE-251 10 mg/kg monthly achieved mean unadjusted dystrophin 3.22% (7.64% muscle-adjusted) vs 0.30% for weekly eteplirsen.","DYNE-251 showed trends in functional endpoints: NSAA, SV95C, 10-Meter Walk/Run, and Time to Rise at 6 months.","Favorable safety for both; FDA accelerated approval pathways confirmed; registration pathway update expected by end of 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-142232","json":"https://secwatch.observer/filing/0001193125-24-142232.json","markdown":"https://secwatch.observer/filing/0001193125-24-142232.md","text":"https://secwatch.observer/filing/0001193125-24-142232.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1818794/000119312524142232/0001193125-24-142232-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1818794/000119312524142232/d821973d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T13:11:06.587185+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}